Drug Trial Radar · NCT05277051
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
152
Actual
Start
Mar 22, 2022
Primary completion
Jun 30, 2026
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Mar 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.
Conditions
- Neoplasms
Interventions
RemzistotugDrug
Remzistotug will be administered.
DostarlimabDrug
Dostarlimab will be administered.
BelrestotugDrug
Belrestotug will be administered.
NelistotugDrug
Nelistotug will be administered.
GSK5764227Drug
GSK5764227 will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Arms A, B, C, I: Number of Participants with dose-limiting toxicities (DLTs)Time frame: Up to 21 days
- Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 27 months
Locations
26 sites in 9 countries. Site status is shown where the registry gives one.
GSK Investigational Site
San Francisco, California
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Oklahoma City, Oklahoma
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
Salt Lake City, Utah
GSK Investigational Site
Nedlands, Western Australia, Australia
GSK Investigational Site
Ottawa, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Chengdu, China
GSK Investigational Site
Jinan, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Wuhan, China
GSK Investigational Site
Dijon, France
GSK Investigational Site
Lille, France
GSK Investigational Site
Chiba, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Málaga, Spain
GSK Investigational Site
Manchester, United Kingdom
GSK Investigational Site
Sutton, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.